In another study, treatment with a pan-JAK inhibitor was shown to inhibit the viability of basal-like cell lines, and a JAK2 inhibitor was shown to reduce tumor growth in murine cell line and primary breast cancer xenograft models (66). This evidence concerns the gene JAK2 and breast cancer.